Savant Capital LLC Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Savant Capital LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 777 shares of the company’s stock after acquiring an additional 168 shares during the period. Savant Capital LLC’s holdings in IDEXX Laboratories were worth $431,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Blair William & Co. IL boosted its holdings in IDEXX Laboratories by 0.7% in the third quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after acquiring an additional 7,812 shares in the last quarter. Morgan Stanley boosted its stake in shares of IDEXX Laboratories by 4.7% during the 3rd quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock valued at $465,482,000 after purchasing an additional 48,095 shares in the last quarter. Northern Trust Corp increased its position in shares of IDEXX Laboratories by 7.7% during the third quarter. Northern Trust Corp now owns 919,191 shares of the company’s stock valued at $401,935,000 after buying an additional 65,891 shares during the period. Principal Financial Group Inc. increased its position in shares of IDEXX Laboratories by 1.4% during the third quarter. Principal Financial Group Inc. now owns 815,863 shares of the company’s stock valued at $356,753,000 after buying an additional 11,315 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in IDEXX Laboratories by 8.9% in the third quarter. JPMorgan Chase & Co. now owns 801,274 shares of the company’s stock worth $350,373,000 after buying an additional 65,760 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.0 %

NASDAQ IDXX opened at $480.60 on Monday. The stock’s fifty day moving average price is $523.29 and its 200-day moving average price is $513.58. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.40. The stock has a market cap of $39.69 billion, a P/E ratio of 46.52, a P/E/G ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. IDEXX Laboratories’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.05 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,524 shares of company stock worth $24,871,960. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on IDXX. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a report on Tuesday, January 30th. Finally, The Goldman Sachs Group increased their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $580.88.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.